Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback